ADAPTABLE Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness

C Adaptable

The Aspirin Study

Schuyler Jones, MD On behalf of the entire ADAPTABLE study team

May 15, 2021


ACC Late-Breaking Clinical Trial presentation

pcornet



ACC.21






Acetylsalicylic acid



2014 AHA/ACC NSTE-ACS Guidelines

I lla llb Ill



For patients who experience NSTE-ACS, a maintenance dose of aspirin (81 mg/d to 325 mg/d) should be continued indefinitely.





Research Question

In patients with established or pre-existing cardiovascular disease, is a strategy of 81 mg or 325 mg of aspirin better?

Everyday decision for patients (OTC medication)



The correct dose of aspirin may **PREVENT**:

Thousands of deaths / heart attacks or Thousands of bleeds *Annually in the United States*



Main Objectives of the ADAPTABLE Trial

To compare the effectiveness and safety of two doses of aspirin (81 mg and 325 mg) in high-risk patients with coronary artery disease.

- Primary Effectiveness Endpoint: Composite of all-cause mortality, hospitalization for MI, or hospitalization for stroke
- Primary Safety Endpoint: Hospitalization for major bleeding that was associated with a blood product transfusion



Statistical Considerations

C Final Trial Sample Size = 15,000

- At least 88% power to detect 15% RRR, assuming primary effectiveness outcome rate of 4.6% per year in higher-risk arm
- Minimum follow-up = 18 mo; maximum follow-up = 50 mo


C Statistical Analysis Plan

- Intention-to-treat
- Cumulative event rates accounting for competing risks of death
- Cox proportional hazards models for event-free survival



ADAPTABLE Study Design

15,000 patients with known ASCVD + ≥ 1 "enrichment factor"





ClinicalTrials.gov: NCT02697916

ADAPTABLE Inclusion Criteria

ADAPTABLE

Exclusion

Known Cardiovascular Disease

- ✓ Prior myocardial infarction
- Prior revascularization (PCI or CABG)
- Prior angiogram showing significant CAD
- History of chronic ischemic heart disease, CAD, or ASCVD



✓ Cerebrovascular disease

✓ Age \ge 65 years

✓ Diabetes mellitus

 Peripheral artery disease

≥ 1 Enrichment Risk Factor

✓ Creatinine \ge 1.5 mg/dL

✓ Known 3-vessel CAD

- ✓ Current smoker
- ✓ Known LVEF < 50%
- Chronic systolic or diastolic heart failure
- ✓ SBP ≥ 140 (within past 12 mos)
- ✓ LDL ≥ 130 (within past 12 mos)

- X History of significant allergy to aspirin
- X History of GI bleeding within 12 months
- X Bleeding disorder that precludes the use of aspirin
- X Current or planned used of an oral anticoagulant or ticagrelor
- X Female patients who were pregnant or nursing



Criteria

Patient Engagement

PATIENT BLOGS

Adaptable



FACEBOOK LIVE

determine the best dose of aspirin to prevent heart attacks or strokes for these patients.

heart disease, you may qualify.

Study enrollment and followup will be done entirely online or over the phone. You will not have to visit a clinic for the study.

Visit us online at AdaptablePatient.com/ and enter your unique code: H2XXX

PATIENT ENGAGEMENT PAVILION



Endpoint Confirmation


- C Data sources:
 - Participant report
 - EHR data

Claims data

- 1. Private insurance (Aetna, Anthem, Humana) data
- 2. CMS (fee-for-service Medicare) data
- Nonfatal endpoints defined by ICD-10 algorithms
- CAll-cause death captured by EHR, health insurance claims, or proxy




40 Study Centers within PCORnet®





Study Flow



C Adaptable

Baseline Characteristics

	81 mg group	325 mg group
Age, median, (25th, 75th), years	67.7 (60.7, 73.6)	67.5 (60.7, 73.5)
Female sex, no. (%)	2307 (30.6%)	2417 (32.1%)
Race, Black or African American, no. (%)	664 (8.8%)	647 (8.6%)
Race, White, no. (%)	6014 (79.8%)	5976 (79.3%)
Hispanic ethnicity, no. (%)	249 (3.3%)	232 (3.1%)
Weight, median (25th, 75th), kg	90.0 (78.6, 103.6)	90.0 (78.2, 104.1)
Current Tobacco use, no. (%)	696 (9.2%)	686 (9.1%)
Aspirin use before study		
81 mg	5823/6850 (85.0%)	5724/6687 (85.6%)
162 mg	168/6850 (2.5%)	142/6687 (2.1%)
325 mg	845/6850 (12.3%)	812/6687 (12.1%)
Dual antiplatelet use at baseline	1570 (22.5%)	1511 (22.1%)



Medical History


	81 mg group	325 mg group
Prior PCI	3005 (40.0%)	2941 (39.1%)
Prior CABG	1786 (23.8%)	1741 (23.2%)
Prior myocardial infarction	2674 (35.6%)	2631 (35.0%)
Hypertension	6264 (83.3%)	6248 (83.1%)
Dyslipidemia	6472 (86.1%)	6474 (86.1%)
Diabetes mellitus	2820 (37.5%)	2856 (38.0%)
Atrial fibrillation	605 (8.0%)	628 (8.4%)
Congestive heart failure	1718 (22.8%)	1786 (23.8%)
Prior GI hemorrhage	455 (6.1%)	495 (6.6%)
Prior intracranial hemorrhage	98 (1.3%)	110 (1.5%)



Medical history was obtained from EHR queries, with look back of 5 years

Primary Effectiveness Endpoint


(All-cause death, hospitalization for MI, or hospitalization for stroke)





Primary Safety Endpoint

(Hospitalization for major bleeding with associated blood product transfusion)



C Adaptable

Effectiveness and Safety Outcomes

	81 mg group N=7434	325 mg group N=7330	HR (95% CI)
Primary endpoint	590 (7.28%)	569 (7.51%)	1.02 (0.91 - 1.14)
Major bleeding	53 (0.63%)	44 (0.60%)	1.18 (0.79 - 1.77)
All-cause death	315 (3.80%)	357 (4.43%)	0.87 (0.75 - 1.01)
Non-fatal MI	228 (2.99%)	213 (2.87%)	1.06 (0.88 - 1.27)
Non-fatal stroke	102 (1.23%)	92 (1.27%)	1.09 (0.82 - 1.45)
PCI or CABG	471 (6.05%)	446 (5.96%)	1.04 (0.92 - 1.19)



		81 mg dose N (Rate)	325 mg dose N (Rate)						HR	(95%	CI)
Subgroup	Overall	590 (7.28%)	569 (7.51%)						1 02	(0.91 - <i>1</i>	1 14)
		000 (1.2070)	000 (1.0170)				1		1.02	(0.01 -	
Analyses	Age >= 65 yrs	364 (7.12%)	378 (7.96%)						0.94	(0.79 - ^	1.12)
(Primary effectiveness	< 65 yrs	226 (7.54%)	191 (6.80%)							(1.00 - 1	,
endpoint)	Sex										
	Female	186 (7.79%)	193 (8.43%)						0.99	(0.81 - 1	1.21)
	Male	404 (7.06%)	376 (7.08%)				-		1.03	(0.90 - 1	1.19)
	Race										
	White	432 (6.70%)	433 (7.12%)							(0.85 - ´	,
	Black	91 (12.27%)	68 (10.69%)					_		(0.99 - ´	,
	Other	33 (6.88%)	33 (7.69%)				•		0.86	(0.53 - ´	1.39)
	Ethnicity										
	Hispanic	24 (7.67%)	14 (5.94%)							(0.83 - 3	,
	Not Hispanic	530 (7.26%)	513 (7.44%)				-		1.01	(0.89 - 1	1.14)
	Diabetes										
	No	283 (5.97%)	258 (5.82%)				- =			(0.89 - 1	,
	Yes	288 (9.28%)	295 (9.99%)				-		0.99	(0.84 - ′	1.17)
	Chronic kidney disease										
	No	370 (5.82%)	347 (5.65%)				-			(0.90 - 1	
	Yes	201 (13.73%)	206 (15.68%)						0.97	(0.80 - 1	1.18)
	P2Y12 inhibitor use										
	No	359 (5.87%)	361 (6.64%)				-			(0.83 - 1	,
	Yes	188 (11.49%)	161 (10.08%)						1.16	(0.94 - 1	1.44)
	Study visit method										
	Interent	439 (6.28%)	449 (6.70%)							(0.85 - 1	,
	Non-Internet	151 (13.73%)	120 (12.96%)				+		1.18	(0.93 - 1	1.50)
				f	avors 81	ma dos	se favo	rs 325 mg d	lose		
				0.125	0.25	0.5	1	2 4			
Adaptable			,	0.120	0.20	0.5	I	∠ 4			

Study Medication in ADAPTABLE

	Overall	81 mg	325 mg
Dose switching, % *	24.2%	7.1%	41.6%
Aspirin discontinuation, % **	9.1%	7.0%	11.1%
Median days of exposure, <u>assigned</u> aspirin dose	551 days (139 - 737)	650 days (415 – 922)	434 days (139 – 737)
Median days of exposure, <u>any</u> aspirin dose	658 days (426 - 932)	670 days (439 – 944)	646 days (412 – 922)

* Defined as at least one dose change

** Reasons for aspirin discontinuation:

25% participant did not want to continue

75% doctor's decision or medical condition (e.g., atrial fibrillation, dyspepsia)



Sensitivity Analyses

Outcome	81 mg dose N (rate)	325 mg dose N (rate)	HR (95% Cl) 325 mg vs 81 mg				
Impact of actual dose taken							
Death / MI / Stroke	673 (3.6 events per 100 patient-years)	321 (2.9 events per 100 patient-years)	1.25 (1.10 - 1.43)				

Rates are calculated at median follow-up (26.2 months) using the Kalbfleisch & Prentice cumulative incidence function estimator.

Rates and HR reflect the effect of the time-varying reported dose on the primary effectiveness end point.

Rates are calculated as annualized event rates (events per 100 patient-years).



Strengths and Limitations

- We successfully completed this virtual, pragmatic study
- We performed this study in a real-world environment, utilized multiple, heterogeneous datasets, and engaged patient-partners to make our study better
- Copen-label study
 - Inability to blind study drug may have affected adherence, dose switching, and drug discontinuation
- Improving diversity and inclusion remains an important goal and may not be fully addressed with virtual studies



Conclusions

- No observed difference in death / MI / stroke in patients assigned to 81 mg vs. 325 mg
- There was a difference in fidelity to the study dose/intervention (more dose switching in 325 mg group)
 - Multiple reasons that patients did not stay on the 325 mg dose
 - Tolerability
 - Medical reasons
 - Participant preferences
 - Clinician practices



Messages to Patients

- If you are on 81 mg now, staying (rather than switching) is probably right given the similar study results for the primary endpoint
- If you are resuming aspirin, starting a lower dose (81 mg) is probably right due to better tolerability and we did not find conclusive evidence that higher dose is better
- If you are tolerating 325 mg now, staying on this dose may be okay and associated with moderate benefit







Thanks!

- The dedication of thousands of participants
- Our partners (ADAPTORs, investigators, researchers)
- C PCORI





Study Organization and Leadership



Study Co-Chairs: Robert Harrington (Stanford) Russell Rothman (Vanderbilt) Data Safety Monitoring Board: Clyde Yancy (Northwestern) – Chair Dave Demets (Wisconsin) Judith Hochman (NYU) Bernard Gersh (Mayo) Alice Jacobs (Boston Med Center) Debbe McCall (patient representative) Hugo Campos (patient representative)

Clinical Coordinating Center (DCRI): Adrian Hernandez (Co-PI) Matthew Roe (Co-PI) Schuyler Jones (Co-PI) Lisa Berdan (Clinical Operations Lead) Holly Robertson (Project Leader) Amber Sharlow (Clinical Research Associate) Data Coordinating Center (DCRI): Lesley Curtis (DCC PI) Brad Hammill (Biostatistician) Debra Harris (Bioinformatics) Laura Qualls (Bioinformatics) Hillary Mulder (Lead Statistician) Lisa Wruck (Senior Statistician) Michael Pencina (Senior Statistician)

PCORI

ADAPTORS:

Desiree Davidson (CAPriCORN) Kevin Edgley (GPC) Greg Merritt (LHSNet) Linda Brown (Mid-South/STAR) Henry Cruz (NYC) Nadine Zemon, Bill Larsen (OneFL) Tom McCormick (PaTH) Jacqueline Alikhaani (pSCANNER) Ken Gregoire (REACHnet)

> Health eHeart PPRN: Greg Marcus Mark Pletcher Madelaine Faulkner Modrow



Simultaneous Publication

